We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Alliance to Develop In Vitro Diagnostics

By HospiMedica staff writers
Posted on 19 Dec 2005
A collaborative agreement between Focus Diagnostics (Herndon, VA, USA) and Stratagene Corp. (La Jolla, CA, USA) has been announced, whereby Focus will develop and commercialize infectious disease molecular products, supplied by Stratagene, for the worldwide clinical in vitro diagnostic (IVD) market.

Under the terms of the agreement, Stratagene will license its nucleic acid amplification technology, called Full Velocity, and associated know-how to Focus for the development of the molecular diagnostic products. In return, Stratagene will manufacture and supply diagnostic products for Focus to sell worldwide and will also supply reagents for Focus to use in performing molecular diagnostic testing services in its reference laboratory.

By using nucleic acid-based diagnostics for the detection of DNA or RNA, laboratories can now deliver results within hours, allowing patients to be treated sooner than before. Amplified nucleic acid testing is much more sensitive today and can detect microorganisms even in very low concentrations.

While the molecular diagnostics market segment now accounts for only 5% of the IVD market, it is expected to grow rapidly because of the increasing investment being made by the IVD industry in this area, according to Focus Diagnostics. By 2010, revenues in the molecular diagnostics market are forecast to reach U.S.$3.7 billion, which represents an annual growth rate of more than 20%. Infectious disease testing comprises the largest and fastest growing segment of the nucleic acid testing market.

"Our comprehensive evaluation of Stratagene's Full Velocity chemistry has convinced us of its exceptional performance characteristics in terms of speed, sensitivity, and overall competitiveness,” said Charles C. Harwood, Jr., CEO of Focus Diagnostics. "Our intention is to bring to market an innovative collection of [U.S.]FDA (Food and Drug Administration)-cleared molecular products that will enable more laboratories to conduct testing that produces actionable results important to patient care.”





Related Links:
Focus Diagnostics
Stratagene

New
Gold Member
X-Ray QA Meter
T3 AD Pro
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
New
LED Surgical Light
Convelar 1670 LED+/1675 LED+/1677 LED+
New
Diagnosis Display System
C1216W

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024